Roger's 1998 Short Picks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Roger's 1998 Short Picks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bob Trocchi who wrote (17707)	3/22/1999 9:13:00 PM
From: BDR	Read Replies (2) of 18691

Re: ZONA, et al. I was scanning the abstracts to be presented at the national AUA meeting the first week of May and counted the number of abstract titles that mentioned various impotence treatments. For the products currently on the market here in the U.S. or other countries the results are: Sildenafil(Viagra).........15 Alprostadil (MUSE)..........4 Injections(Edex or other)...2 Phentolamine(Vasomax)......Zero Looks like Vasomax is not exactly a focus of intense research activity. Other modalities mentioned: Apomorphine................3 Gene therapy...............2 Melanotan II...............1 Potassium channel opener...1 IC351......................1 Results subject to error due to my inability to add correctly. Disclaimer: I am long Pfizer, short ZONA and I couldn't care less about VVUS.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next